Third Eye will know more than us.

4.22 BETonMACE Phase III Trial

Schedule 4.22 hereto sets forth as of the Closing Date, a true and accurate summary of the clinical trial protocol and achievements to-date including (i) target sample size, (ii) current enrolment size, (iii) primary and secondary endpoints, (iv) list of participating sites; (v) average patient profile; (vi) description of drug, dosing, and route of administration; (vii) target duration of study and current status, (viii) target participation duration of patients; (ix) target events and events to-date; (x) target relative risk reduction and relative risk reduction to-date; (xi) events until interim analysis; (xii) assumed dropout rate and rate-to-date